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Introduction: The neuronal loss in Alzheimer disease (AD) has been described to affect grey matter in the cerebral
cortex. However, in the elderly, AD pathology is likely to occur together with subcortical axonal degeneration on
the basis of cerebrovascular disease. Therefore, we hypothesized that biomarkers for AD and subcortical axonal
degeneration would correlate in patients undergoing testing for dementia biomarkers, particularly in older age
groups.
Methods: We performed correlation and cluster analyses of cerebrospinal fluid (CSF) biomarker data from 5,542 CSF
samples analyzed in our routine clinical neurochemistry laboratory in 2010 through 2012 for the established CSF AD
biomarkers total tau (T-tau), phosphorylated-tau (P-tau), amyloid β1-42 (Aβ42), and for neurofilament light (NFL),
which is a protein expressed in large-caliber myelinated axons, the CSF levels of which correlate with subcortical
axonal injury.
Results: Aβ42, T-tau, and P-tau correlated with NFL. By cluster analysis, we found a bimodal data distribution in
which a group with a low Aβ42/P-tau ratio (suggesting AD pathology) had high levels of NFL. High levels of NFL
also correlated with the presence of an AD biomarker pattern defined by Aβ42/P-tau and T-tau. Only 29% of those
with an AD biomarker signature had normal NFL levels. Age was a possible confounding factor for the associations
between NFL and established AD biomarkers, but in a logistic regression analysis, both age and NFL independently
predicted the AD biomarker pattern.
Conclusions: The association between an AD-like signature using the established biomarkers Aβ42, T-tau, and P-tau
with increased levels of NFL provides in vivo evidence of an association between AD and subcortical axonal
degeneration in this uniquely large dataset of CSF samples tested for dementia biomarkers.Introduction
A growing interest exists in the role of mixed pathologies
for development of symptomatic Alzheimer disease (AD).
The canonic brain hallmarks of AD are extracellular
β-amyloid (Aβ) deposits and intracellular tangles com-
posed of tau proteins, but the correlations between these
findings and dementia symptoms decline with increasing
age [1]. Although pathologic Aβ metabolism is clearly the
initiating event in autosomal dominant AD, sporadic AD
may be a more heterogeneous etiology, with, for example,* Correspondence: tobias.skillback@neuro.gu.se
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reproduction in any medium, provided the orcerebrovascular pathology contributing to symptoms in
some patients [2]. A large overlap in pathology is noted
between elderly AD patients and individuals dying of
other causes [3-5], which might be explained by combined
effects of Alzheimer-type and cerebrovascular pathology
in the form of white-matter lesions actually leading to
dementia in elderly AD patients [6]. This is supported
by neuropathologic studies showing increased frequency
of mixed pathologies rather than pure AD pathology in
dementia patients in older age groups [7].
Cerebrospinal fluid (CSF) biomarkers have become in-
creasingly important in dementia research and have been
included in research diagnostic criteria for AD [8-10].
The most well-established CSF AD biomarkers are the
42-amino-acid isoform of Aβ (Aβ42), total-tau (T-tau),l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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reflect the presence of amyloid plaque deposition, axonal
degeneration, and neurofibrillary tangles, respectively [11].
Another CSF biomarker for neuroaxonal injury is neurofila-
ment light (NFL) protein. NFL is expressed predominantly
in large-caliber myelinated axons [12], and its CSF levels
correlate with white-matter lesions and other injuries to
subcortical brain regions [13-18]. NFL is often normal
in clinically pure AD [19] but abnormal in the presence
of vascular pathology (for example, small-vessel disease
[20], which mainly affects subcortical brain regions). NFL is
also elevated in several other pathologic conditions, such as
frontotemporal dementia (FTD) [21,22], MS [23], idiopathic
normal-pressure hydrocephalus [24], ALS [25], and various
CNS infections [26-28]. Mutations in the NFL gene cause
Charcot-Marie-Tooth disease [29].
Here, our main goal was to explore in vivo relations
between pathologic hallmarks of AD and subcortical
axonal damage, by using CSF biomarkers. Because the
influence of vascular pathology and other causes of injury
to subcortical brain regions in the general AD population
may be underestimated in small cohorts with selected AD
patients, we performed a study of CSF biomarkers in a
uniquely large sample set from our clinical routine
practice. This included mainly samples from memory
clinics, geriatric clinics, and neurology clinics. In this
unselected material, we hypothesized that a positive CSF
AD biomarker signature, with reduced Aβ42 and elevated
T-tau and P-tau, would often be seen in combination with
elevated NFL, because of the presence of mixed pathology,
particularly in the older age groups. We assumed that the
main cause of elevated NFL was subcortical vascular
disease, but it is possible that NFL may also be elevated
because of increased axonal loss in general, or secondary to
amyloid angiopathy, which may accompany and correlate
with AD pathology, and lead to cerebrovascular pathology.
Methods
This was a cross-sectional study, using archived data on
CSF Aβ42, T-tau, P-tau, and NFL measurements from
January 1, 2010, to June 1, 2012, extracted from the
database of clinical routine test results at the Mölndal
site of the Sahlgrenska University Hospital, Sweden. All
test results were obtained for diagnostic purposes. The
inclusion criteria were that patients were older than
30 years at sampling, and that all four CSF analyses had
been requested by the clinician. The majority of the
samples were ordered from geriatric clinics, neurology
clinics, and memory clinics. For patients tested more
than once during the study period (N = 126), only the first
sample was used. In all, the study included 5,442 samples.
Because this was a registry study, the concept of informed
consent was not applicable. The laboratory receives samples
from many different clinical sites in Sweden, so we did nothave access to medical records, CSF cell counts, or total
protein levels. This makes us unable to rule out cases of
infectious, inflammatory, or acute cerebrovascular disease
in this cohort.
Biochemical measurements
CSF Aβ42, T-tau, and P-tau were measured by using
enzyme-linked immunosorbent assay (ELISA) assays
(INNOTEST β-amyloid [1–42], hTau Ag, and Phospho-tau
[181P]; Innogenetics) as previously described [30,31]. The
between-assay coefficients of variation (CV) for the Aβ42,
T-tau, and P-tau tests were 13.4%, 11.3%, and 9.70%, re-
spectively (as determined by internal control samples dur-
ing the entire study period). CSF NFL was measured with a
novel, sensitive sandwich ELISA method (NF-light ELISA
kit; UmanDiagnostics AB, Umeå, Sweden), as described by
the manufacturer. The lower limit of quantification for this
assay was 50 ng/L. The between-assay CV for the NFL as-
says was 14.0%. For further details on these measurements,
see Appendix A.
For the AD biomarkers, we used cut-offs previously
generated at our laboratory, in a study with long follow-up
time of early-stage AD patients, in which the combination
of T-tau and Aβ42/P-tau ratio had 95% sensitivity and 87%
specificity [32]. With these cut-offs (T-tau > 350 ng/L;
Aβ42/P-tau < 6.5), our dataset was divided into groups
of sample profiles matching the AD biochemical profile
(26.9%) or not (73.1%).
For NFL, we defined a threshold value for subcortical
axonal degeneration by using an independent dataset on 108
CSF samples from clinically examined neurologically healthy
volunteers (age median, 38 years; range, 18 to 76 years). The
95th percentile for CSF NFL in this group gave us a thresh-
old value of 1,400 ng/L. This dataset forms the basis for the
clinical normal reference limits for the UmanDiagnostics
NFL assay at the Sahlgrenska Mölndal laboratory.
All analyses were performed in clinical routine by board-
certified laboratory technicians with procedures accredited
by the Swedish Board for Accreditation and Conformity
Assessment (SWEDAC). Longitudinal stability in the
measurements over years was ascertained by using an
elaborate system of internal quality control samples and
testing of incoming reagents (Appendix A).
Variables
The outcomes were relations between NFL levels and
the AD biomarkers. In particular, we were interested in
the frequency of patients with increased NFL levels among
patients with a positive AD biomarker pattern. Age and
sex were potential confounders.
Statistics
Correlations were calculated by using the Spearman
rank correlation coefficient, and statistical hypothesis
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gression, ANOVA, multiple regression, or Mann–Whitney
U tests. Outliers in data were identified by the Grubbs test
for outliers and excluded from the dataset before analysis.
These general statistics and all charts and tables were
produced in SPSS version 20 (IBM, New York, NY, USA).
Logarithmic transformations were used to fit the signifi-
cantly skewed NFL data for logistic regression analysis
and multiple regression. Figure axes are presented with
logarithmic axes where specified in axis title.
Clustering was performed in JMP version 10.0.0 (SAS
Institute Inc., Cary, NC, USA) by using the K-means
clustering algorithm. K-means clustering is a special case
of a general approach called the EM algorithm, where E
stands for Expectation (the cluster means in this case),
and M stands for Maximization, which in this case means
assigning points to the closest clusters. Distance is mea-
sured by the squared euclidian distance of each point,
assigning each data point to the cluster that yields the
least within-cluster sum of squares. To choose the optimal
number of clusters, we used the cubic clustering criterionTable 1 Demographics
Age group Sex
F M
All Valid N 50.8% 49.2%
Mean (SD) 60
Median (range) 54
31-40 Valid N 51.3% 48.7%
Mean (SD) 73
Median (range) 70
41-50 Valid N 52,.% 47.7%
Mean (SD) 73
Median (range) 70
51-60 Valid n 52.2% 47.8%
Mean (SD) 72
Median (range) 70
61-70 Valid n 48.9% 51.1%
Mean (SD) 62
Median (range) 58
71-80 Valid n 49.6% 50.4%
Mean (SD) 55
Median (range) 50
81-90 Valid n 55.1% 44.9%
Mean (SD) 52
Median (range) 46
91+ Valid n 53.8% 46.2%
Mean (SD) 48
Median (range) 49(CCC), in which the possible numbers of clusters are com-
pared with each other in terms of their within-cluster sum
of squares [33].
Ethics
The study was approved by the regional ethics committee
at the University of Gothenburg.
Results
Dataset description
Demographics are summarized in Table 1. The majority of
patients were from 60 to 90 years old (M, 70.1; SD, 11.0),
and the sex distribution was even.
CSF AD biomarkers in relation to NFL levels
We first analyzed the relation between NFL and the other
biomarkers in the overall study population (Figure 1).
Both T-tau and P-tau had positive correlations with NFL
(Figure 1A,B; R = 0.416; P ≤ 0.001 for T-tau and r = 0.231,
P ≤ 0.001 for P-tau), whereas Aβ42 had an inverse correl-
ation with NFL (Figure 1C; r = −0.130; P ≤ 0.001).Aβ42 T-tau P-tau NFL
5,542 5,542 5,542 5,542
2 (286) 504 (953) 60 (33) 3,007 (6,935)
4 (1,725) 360 (32,125) 52 (283) 1,530 (226,920)
78 78 78 78
3 (309) 262 (229) 38 (20) 1,974 (6,056)
4 (1,420) 194 (1,325) 35 (122) 460 (45,790)
237 237 237 237
9 (304) 302 (494) 39 (18) 1,856 (5,790)
7 (1,725) 210 (6,025) 35 (122) 520 (66,220)
688 688 688 688
3 (297) 458 (1,354) 49 (30) 2,788 (8,719)
0 (1,612) 258 (27,525) 42 (206) 870 (100,810)
1,539 1,539 1,539 1,539
6 (289) 464 (947) 55 (30) 2,931 (6,609)
0 (1,455) 317 (30,425) 48 (283) 1,280 (89,820)
2,069 2,069 2,069 2,069
9 (271) 546 (1,027) 64 (32) 3,026 (7,203)
0 (1,715) 409 (32,125) 57 (240) 1,710 (226,770)
905 905 905 905
3 (247) 581 (349) 72 (34) 3,573 (5,422)
5 (1,535) 479 (3,493) 65 (235) 2,200 (93,130)
26 26 26 26
7 (161) 778 (549) 90 (53) 5,605 (8,049)
6 (785) 590 (2,413) 76 (250) 2,845 (42,000)
A B
DC
Figure 1 Relations between NFL and the other markers included in the dataset. Both T-tau (A) and P-tau (B) tend to increase with higher
levels of NFL, whereas higher levels of Aβ42 (C) correlate with lower levels of NFL. For graphic clarity, the x-axes (NFL) were cut at 7,000 ng/L
(93% of the tested samples had NFL below this level), but all data points (excluding statistical outliers) were included in the statistical analyses.
(D) Result of the K-means clustering algorithm applied to NFL and Aβ42/P-tau in our dataset.
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had interesting features (Figure 1D). The data distribution
contained three separate clusters, with one dense group
consisting of samples with a high Aβ42/P-tau ratio in
combination with low levels of NFL (green cluster), an-
other group with lower Aβ42/P-tau ratio and higher levels
of NFL (red cluster), and a third cluster of outliers with
substantially higher levels of NFL (brown cluster). By
k-means cluster analysis, we could successfully identify
these three groups. By applying CCC, we could confirm
that the division into three clusters was the most efficientway to model these data (CCC = 0.62, which was the
largest CCC (optimal) in the range of one to 20 clusters
[two-cluster CCC = −13.98; four-cluster CCC = −15.23)).
The identified clusters showed the following properties:
(I, green cluster) high Aβ42/P-tau (median = 18.9; mean =
20.0) and low NFL (median = 1,010; mean = 1,158); (II, red
cluster) low Aβ42/P-tau (median = 5.4; mean = 5.5) and high
NFL (median = 1,600; mean = 1,697); (III, brown cluster)
outliers with very high NFL values (median = 4,440;
mean = 4,609) and intermediate Aβ42/P-tau (median = 13.4;
mean = 12.1). The age distribution varied across the clusters
Skillbäck et al. Alzheimer's Research & Therapy 2013, 5:47 Page 5 of 10
http://alzres.com/content/5/5/47(M, SD, I: 65.7, 11.5; II: 74.0, 8.6; III: 73.2, 10.0), with
significant differences when tested with one-way ANOVA
(F(2, 5,154) = 413, 193; P < 0.001).
Biochemical AD criteria versus NFL levels
To search further for associations between AD and
subcortical pathology, we classified the study subjects by
using NFL as a marker of subcortical axonal degeneration,
and Aβ and tau markers for AD, by cut-offs, as explained
earlier (Figure 2). The relative number of NFL-positive
patients was significantly higher in the group of AD
biomarker-positive patients than in the AD biomarker-
negative group (χ2 = 197.0; P ≤ 0.001).
CSF biomarker patterns in different ages
Age is a strong risk factor for both AD and cerebrovascular
pathology, which is a main cause of subcortical axonal
degeneration, and a possible confounder for the relation
between the AD biochemical profile and elevated NFL.
We therefore explored the relation between age and
biomarkers in detail.
First, pathologic levels of all the biomarkers were ex-
plored in the different age groups (Figure 3). The fre-
quency of pathologic levels of Aβ42 was about 30% in
the youngest cohort, started to increase in subjects
from about 60 years of age, and plateaued at about 60%
in patients older than 80 years (Figure 3A). In contrast,
the frequency of pathologic levels of T-tau was only about
15% in the youngest cohort, and increased linearly in
subjects from about age 40 years, reaching 90% in the
oldest cohort (Figure 3B). P-tau had a similar pattern,















Figure 2 More patients in the group with positive AD biomarker patt
percentage relations between the prevalence of normal or increased NFL lold (Figure 3C). Pathologic levels of the Aβ42/P-tau ratio
were seen in only about 5% of subjects in the youngest co-
hort and increased linearly in subjects from about 40 years
of age, reaching 55% in the oldest cohort (Figure 3D).
The pathologic combination of all three AD biomarkers
(AD biomarker profile) had a similar pattern (Figure 3E).
Pathologic levels of NFL were seen in about 20% in the
youngest cohort and showed a sigmoidal increase, reaching
about 90% in the oldest cohort (Figure 3F).
Figure 4 displays the groups of AD biomarker-positive
and -negative patients, and the prevalence of increased NFL
levels in different age groups. It was more common among
AD biomarker-positive patients to have low NFL levels in
younger than in older patients (although the number of
young patients with the AD biochemical profile was small),
but the fraction of NFL-positive subjects increased with
age, in both the AD-positive and AD-negative groups. To
adjust for the effect of age, we did a logistic regression
analysis with age and NFL as predictors of the AD bio-
marker profile (dichotomized as positive or negative). Both
age (B = −0.063; P ≤ 0.001; exp(B) = 0.939) and log(NFL)
(B = −0.685; P ≤ 0.001, exp(B) = 0.504) were significant pre-
dictors when used as single predictors, and when used
together in the model (Age, B = −0.060, P < 0.001, exp(B) =
0.941, log(NFL): B = −0.246, P = 0.005, Exp(B) = 0.782).
Figure 5 shows NFL values versus age, and LOESS fit
lines for the AD biomarker profile- positive and -negative
groups. In younger ages, NFL levels were higher in the
biomarker-positive group (although the few available AD
biomarker-positive young subjects makes these estimates
uncertain), but the fitted lines for the positive and negative
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Figure 3 Pathologic levels of biomarkers in different age groups. (A-D) Shares of subjects with presumed pathologic levels of the
CSF biomarkers Aβ42, T-tau, P-tau, and Aβ42/P-tau-ratio, in that order. For NFL (E), we defined a cut-off by using an independent
dataset on 108 CSF samples from clinically examined neurologically healthy adults (age median, 38 years; range, 18 to 76 years). For
the AD biomarkers (F), we used cut-offs previously generated at our laboratory, in a study with long follow-up time of early-stage
AD patients.
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and did not solely rely on the relatively high levels of NFL
among younger subjects (as shown in Figures 4 and 5),
the data were split into two age categories, with 65 years
as break point. A Mann–Whitney U test confirmed that
the NFL levels in the AD biomarker-positive groups was
significantly higher for both age groups (H(1) = 68.6,P < 0.001 for ages younger than 65), and (H(1) = 41.53;
P < 0.001 for ages older than 65).
To assess the importance of different factors in an ad-
justed model, a multiple linear regression was performed
to predict NFL from sex, age, and AD biomarker profile
(dichotomized as positive or negative). These variables sta-


































Figure 4 The prevalence of subjects with increased NFL levels in patient groups who fulfill AD biomarker criteria or not, and how they
develop with age. Patients with a positive AD biomarker pattern display elevated levels of NFL more often than do patients with a negative AD
biomarker pattern, but the gap between the two groups closes with age.
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statistically significant (age (years): β = 0.352, P < 0.001;
sex (female): β = 0.128; P < 0.001; AD-biomarker profile
(positive): β = 0.043; P = 0.001).
Discussion
In a uniquely large dataset of clinical routine samples,
we tested associations between established CSF biomarkers
for AD pathology (Aβ42, T-tau, and P-tau) and a CSF
biomarker for subcortical axonal degeneration (NFL).
In this unselected population of patients from memory
clinics, geriatric clinics, and neurology clinics, we expected
to find a large proportion of subjects with positive AD
biochemical profile, suggesting the presence of AD, and
a large proportion with elevated NFL levels, suggesting
the presence of cerebrovascular or other white-matter
disease. This was confirmed, but we also found an associ-
ation between white-matter disease, as reflected by NFL
levels and AD, as reflected by Aβ42, T-tau, and P-tau
levels. Subjects with a positive AD biomarker profile often
also had high NFL levels. Only 29% of the subjects with
positive AD biomarker profile had normal NFL levels,
suggesting that a pure AD biochemical profile without
signs of NFL leakage is unusual in subjects undergoing
testing for dementia biomarkers. In contrast, elevated NFL
was rare in the AD biomarker-negative group. It should benoted that NFL is believed to be a marker of white-matter
disease because it is predominantly expressed in myelinated
large-caliber axons [12]. However, other types of injury
to such neurons (not only white matter lesions) could
also lead to higher NFL levels in CSF.
Cluster analysis showed three clusters in our data;
the first large group had high Aβ42/P-tau quota and
low NFL (that is, weak biochemical support for either
AD or subcortical pathology). The second equally large
cluster had low Aβ42/P-tau quota and high NFL (that is,
for concomitant AD and subcortical pathology), whereas
the third, considerably smaller cluster had the highest
levels of NFL and intermediate Aβ42/P-tau quota, suggest-
ing predominant subcortical pathology or other reasons for
NFL leakage. This was a cross-sectional study, so we cannot
make conclusions on the order of pathologic events under-
lying these biomarkers, but a possible explanation for the
identified biomarker distributions is that AD pathology is
strongly associated with vascular pathology, because NFL
levels have previously been found to correlate with vascular
pathology [15,19,34]. Alternative explanations to our find-
ings may be that the increased NFL levels are caused by
high cell loss or increased amyloid angiopathy in AD, or a
combination of all these factors.
The cluster with the most normal pattern of Aβ42, P-tau,
and NFL (indicating least brain engagement) had the
Figure 5 A plot of NFL levels in patient groups who fulfill AD biomarker criteria or not, and how they develop with age. Patients with a
positive AD biomarker pattern display elevated levels of NFL more often than do patients with a negative AD biomarker pattern, but the gap
between the two groups closes with age.
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lected group of patients. In a detailed analysis of the
relation between biomarkers and age, we observed that
the prevalence of high NFL levels increased with age,
and we noted that this was seen in patients both with
and without the AD biomarker profile. The group with
a positive AD biomarker profile had the highest levels
of NFL. This difference was greater among the younger
patients, and the gap between the groups closed with
increasing age, but age and NFL were still independent
predictors of the AD biomarker profile in a logistic regres-
sion analysis. When dichotomized into subjects younger or
older than 65 years, AD biomarker-positive subjects had
significantly higher NFL levels in both age groups, tested by
using the Mann–Whitney U test.
The main strength of this study is its unique size; to
our knowledge, it is the largest study ever published on
CSF biomarkers. The main study limitation is the limited
access to clinical data. The absolute majority of analyses
were requested in investigations of cognitive decline. The
study population may therefore be considered to represent
a group of patients with different degrees of cognitive dys-
function. However, at some centers lumbar puncture and
NFL analysis may preferentially be performed in clinicallycomplicated or ambiguous cases, which could bias the
population toward rare or mixed brain pathologies,
and increase the likelihood of finding atypical biomarker
patterns. Because of lack of CSF cell count and total protein
data, we cannot exclude that a few patients with inflamma-
tory or infectious conditions were included. However, this
limitation is unlikely to have influenced the positive associ-
ation between high NFL levels and a positive AD biomarker
profile, as neuroinflammation might increase NFL levels
but not the prevalence of a positive AD biomarker status
[35,36]. The lack of clinical data may partly be compensated
by the known strong association of positive CSF AD bio-
markers with AD pathology [37] and the fact that CSF AD
biomarkers are strong predictors of clinical AD in patients
undergoing cognitive evaluation [11]. The lack of clinical or
imaging data on cerebrovascular disease prevents firm
conclusions regarding the cause of NFL elevations. We
based the association of elevated CSF NFL with cere-
brovascular disease on previous studies [15,19,34].
Conclusions
Biochemical evidence of AD was most often seen together
with elevated NFL levels, which is a biomarker sign com-
patible with subcortical vascular pathology. However, we
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NFL elevations in this patient group, including general
neuronal death or amyloid angiopathy, which may ac-
company AD pathology and lead to cerebrovascular
pathology. The in vivo relation between AD and sub-
cortical axonal degeneration must be further explored
in other cohorts with access to clinical, neuroimaging,
and fluid biomarker data. The results of this study, if
replicated, may be relevant to clinical trials in which
drugs developed against AD pathology are evaluated,
because we show that patients with an AD biochemical
profile are likely to have subcortical axonal degeneration,
which may contribute to the symptoms and explain diffi-
culties in obtaining desired drug effects.
Appendix A
The coefficients of variation (CVs) of the assays for NFL,
Aβ42, T-tau, and P-tau were determined by analyzing re-
cords of measurements of internal control samples that
are routinely carried out at the laboratory at Mölndal at
least twice a week. Control samples are kept in frozen al-
iquots and reused until depleted and then exchanged.
Standard deviations of the averages of all measurements
from each control sample were calculated, and an aver-
age of these standard deviations was used to represent a
CV for every analysis.
For NFL, one low and one high control sample was
used. The first low control was used from January 2010
until May 2010, whereas the first replaced control was
used until January 2011, and the last replaced control was
used until June 2012. The three low controls showed stand-
ard deviations of 15.15%, 15.24%, and 13.24%, respectively.
The first two high controls were used during the same pe-
riods as the first two low controls and measured deviations
of 14.41% and 16.60%, respectively. The third control was
used until May 2012 and had a deviation of 15.32%. The
last control was used between May and June 2012 and had
a deviation of 7.84%. The average of all these deviations
was calculated and resulted in a CV of 14.04%.
For Aβ42, three different low and three different high
controls were used during the study. The first low control
was used from January 2010 until January 2011; the second
one was replaced in May 2012, and the third control was
used the remaining time of the test period. The three low
controls measured standard deviations of 19.42%, 12.76%,
and 12.46%, respectively. The first high control was used
from January 2010 until August 2010; the second one,
until November 2010; the third, until June 2011; and the
last control was used for the remainder of the test period.
The high controls measured standard deviations of 10.45%,
13.14%, 12.62%, and 11.54%. The total average of the Aβ42
measurements was calculated as 13.41%.
For P-tau, three different low, and three different high
controls were used. The first low control was used fromJanuary 2010 until January 2011; the second one was re-
placed in May 2012; and the third control was used the
remaining time of the test period. The three low controls
measured standard deviations of 8.60%, 11.68%, and
11.04%, respectively. The first high control was used from
January 2010 until November 2010; the second one, until
June 2011; and the last control were used for the remainder
of the test period. The high controls measured standard
deviations of 8.62%, 8.85%, and 9.38%. The total average
of the P-tau measurements was calculated to be 9.70%.
For T-tau, three different low, and three different high
controls were used. Both the high and low controls were
replaced at the same time as the ones for P-tau. The
three low controls measured standard deviations of 9.35%,
9.88%, and 9.05%, respectively. The high controls measured
standard deviations of 19.15%, 10.73%, and 9.63%. The
total average of the T-tau measurements was calculated
to be 11.30%.
No measureable longitudinal drift was registered for
any of the analyses.Abbreviations
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